Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)

  • End date
    Jun 15, 2035
  • participants needed
  • sponsor
    Institut Curie
Updated on 27 January 2021


Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.


High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule :

(i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines).

(ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research.

  • M0 : during the first medical oncology visit.
  • At each imaging assessment, every 6 months for at least 5 years (M6 to M60) and 10 years maximum (M120).
  • At the diagnosis of metastasis.
  • At each significant event during the metastatic disease (surgery, treatment response or progression).

Condition Uveal Melanoma
Treatment Blood test
Clinical Study IdentifierNCT04424719
SponsorInstitut Curie
Last Modified on27 January 2021


Yes No Not Sure

Inclusion Criteria

Patient aged of 18 years or more
Patient with uveal melanoma with high metastatic relapse risk defined as
T2b/c/d ou T3
or chromosom 3 or chromosom 8 abnormality by CGH array
Completion of treatment of the primary tumor 2 months
Patient able to comply with the schedule of visits and blood samples of the study
Signed informed consent form or legal representative

Exclusion Criteria

Patient without french social insurance
Any social, medical or psychological condition making the research process impossible
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note